It is very likely that we tackled an Nrf2 decay pathway that functions in cells that are depleted from KEAP1 and deprived of GSK3beta activity (as, e.g., possibly found in cancers with KEAP1 mutation and overactive PI3K signaling). The gene discussed is KEAP1; the disease is cancer.